NMRA
Neumora Therapeutics, Inc.
$1.78
0.00%
$329.8M
No data for this timeframe.
Vol
Market Cap$329.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (80%)
Inst. Holders50 funds
Inst. Value$59.4M
Inst. Activity5 buys / 3 sells
Reddit Sentiment43° Neutral
SEC Reports1
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001885522·Prev Close $1.78
Recent Activity
May 27, 2026
Insider
Halawa Alaa was granted 80,000 shares
Director
May 27, 2026
Insider
Ho Maykin was granted 80,000 shares
Director
May 27, 2026
Insider
Piacquad David was granted 80,000 shares
Director
Apr 17, 2026
SEC
Neumora Therapeutics, Inc. is holding its 2026 annual meeting of stockholders. The proxy statement outlines proposals fo
DEFA14A — Impact 2/10
Inst.
MARSHALL WACE, LLP — DOUBLED
1,195,310 shares ($2.3M)
Inst.
Point72 Asset Management, L.P. — NEAR_EXIT
602,403 shares ($1.2M)
May 20, 2026
short_volume
Short Volume: NMRA — 58.2% short (0.3M / 0.6M)
Short: 340,086 | Exempt: 8 | TRF Vol: 584,076 | Short Ratio: 58.2% | Off-exchange volume (dark pool
Mar 30, 2026
Press
Neumora Therapeutics reported Q4 and full-year 2025 financial results with reduced R&D and G&A expenses, resulting in a
Impact 5/10
Price Targets
$8.91
+400.4% upside
Strong Buy
Current $1.78
Low $3.00
Median $7.63
High $18.00
8 analysts
$3.00
$18.00
Analyst Ratings
5Strong Buy
7Buy
2Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 31, 2026 | Guggenheim | REITERATE | Buy → Buy |
| Mar 31, 2026 | Needham | REITERATE | Buy → Buy |
| Feb 17, 2026 | William Blair | UPGRADE | Market Perform → Outperform |
| Jan 12, 2026 | Leerink Partners | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.24 ▲ +4.1% | $-0.30 — $-0.20 | 26% YoY | 9 |
| Next Q | $-0.23 ▲ +1.8% | $-0.32 — $-0.18 | 35% YoY | 9 |
| Current FY | $-0.96 | $-1.29 — $-0.67 | 33% YoY | 9 |
| Next FY | $-0.89 ▲ +3.6% | $-1.25 — $-0.39 | 8% YoY | 9 |
Latest Reports
NEUTRAL
DEFA14A
2/10
Neumora Therapeutics, Inc. is holding its 2026 annual meeting of stockholders. The proxy statement outlines proposals fo
Apr 17, 2026
MIXED
Press
5/10
Neumora Therapeutics reported Q4 and full-year 2025 financial results with reduced R&D and G&A expenses, resulting in a
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| SOFTBANK GROUP CORP. | $11.9M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $7.6M | — |
| FMR LLC | $6.8M | TRIM |
| BlackRock, Inc. | $4.0M | TRIM |
| TWO SIGMA INVESTMENTS, LP | $4.0M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 27, 2026 | Halawa Alaa | A | $0.00 |
| May 27, 2026 | Ho Maykin | A | $0.00 |
| May 27, 2026 | Piacquad David | A | $0.00 |
| May 27, 2026 | Burow Kristina | A | $0.00 |
| May 27, 2026 | Fust Matthew | A | $0.00 |
Reddit Sentiment
43°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $59.4M total value (30,646,945 shares) as of 2026-Q1. Top holders: SOFTBANK, VANGUARD, FMR. Net buying activity: 5 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | SOFTBANK GROUP CORP. | 6,090,301 | $11.9M | 20.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3,891,893 | $7.6M | 12.8% | — |
| 3 | FMR LLC | 3,498,658 | $6.8M | 11.5% | TRIM -55.4% |
| 4 | BlackRock, Inc. | 2,054,316 | $4.0M | 6.7% | TRIM -37.0% |
| 5 | TWO SIGMA INVESTMENTS, LP | 2,036,692 | $4.0M | 6.7% | DOUBLED +336.2% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 1,388,998 | $2.7M | 4.6% | — |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,240,241 | $2.4M | 4.1% | — |
| 8 | MARSHALL WACE, LLP | 1,195,310 | $2.3M | 3.9% | DOUBLED +104.8% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,000,000 | $1.9M | 3.3% | — |
| 10 | TUDOR INVESTMENT CORP ET AL | 771,418 | $1.5M | 2.5% | — |
| 11 | Point72 Asset Management, L.P. | 602,403 | $1.2M | 2.0% | NEAR_EXIT -83.6% |
| 12 | GOLDMAN SACHS GROUP INC | 568,280 | $1.1M | 1.9% | — |
| 13 | TUDOR INVESTMENT CORP ET AL | 555,200 | $1.1M | 1.8% | — |
| 14 | VANGUARD FIDUCIARY TRUST CO | 535,033 | $1.0M | 1.8% | — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 516,182 | $1.0M | 1.7% | TRIM -25.3% |
| 16 | FRANKLIN RESOURCES INC | 511,084 | $996.6K | 1.7% | — |
| 17 | MORGAN STANLEY | 503,819 | $982.4K | 1.7% | DOUBLED +111.3% |
| 18 | STATE STREET CORP | 398,719 | $777.5K | 1.3% | NEAR_EXIT -79.6% |
| 19 | DIMENSIONAL FUND ADVISORS LP | 354,850 | $691.8K | 1.2% | DOUBLED +230.9% |
| 20 | CITADEL ADVISORS LLC | 343,586 | $670.0K | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | 583,758 | 1,195,310 | +104.8% | $2.3M | 2026-Q1 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 3,673,839 | 602,403 | -83.6% | $1.2M | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 238,484 | 503,819 | +111.3% | $982.4K | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 107,250 | 354,850 | +230.9% | $691.8K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 102,409 | 176,927 | +72.8% | $345.0K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 91,700 | 140,200 | +52.9% | $273.4K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 137,300 | 50,900 | -62.9% | $99.3K | 2026-Q1 |
| CWM, LLC | TRIM | 5,177 | 3,146 | -39.2% | $6.1K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 299,814 | 1,307,688 | +336.2% | $2.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 137,429 | 102,409 | -25.5% | $183.3K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 5,000 | 10,000 | +100.0% | $17.9K | 2025-Q4 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 6,261 | 8,119 | +29.7% | $14.5K | 2025-Q4 |
| CWM, LLC | TRIM | 11,136 | 5,177 | -53.5% | $9.00 | 2025-Q4 |
| BlackRock, Inc. | TRIM | 2,882,109 | 1,815,930 | -37.0% | $3.3M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 588,332 | 299,814 | -49.0% | $545.7K | 2025-Q3 |
| Invesco Ltd. | ADD | 132,038 | 183,799 | +39.2% | $334.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 71,380 | 137,429 | +92.5% | $250.1K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 650,704 | 129,046 | -80.2% | $234.9K | 2025-Q3 |
| SEI INVESTMENTS CO | TRIM | 213,862 | 68,336 | -68.0% | $124.4K | 2025-Q3 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | TRIM | 29,820 | 10,433 | -65.0% | $19.4K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 6,826 | 5,000 | -26.8% | $9.1K | 2025-Q3 |
| CWM, LLC | TRIM | 35,750 | 11,136 | -68.9% | $20.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 3,106,556 | 650,704 | -79.1% | $477.0K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 274,314 | 588,332 | +114.5% | $431.4K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 593,498 | 443,167 | -25.3% | $325.0K | 2025-Q2 |
5 unique insiders with 5 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 27, 2026 | Halawa Alaa | Director | AWARD | 80,000 | — | — |
| May 27, 2026 | Ho Maykin | Director | AWARD | 80,000 | — | — |
| May 27, 2026 | Piacquad David | Director | AWARD | 80,000 | — | — |
| May 27, 2026 | Burow Kristina | Director | AWARD | 80,000 | — | — |
| May 27, 2026 | Fust Matthew K | Director | AWARD | 80,000 | — | — |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.0/10.
Current analyst consensus: Strong Buy (80% buy). Based on 15 analysts: 5 strong buy, 7 buy, 2 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$8.91 mean target
+400.4% upside
Strong Buy (1.78)
$3.00 Low
$18.00 High
| Metric | Value |
|---|---|
| Current Price | $1.78 |
| Target Low | $3.00 |
| Target Mean | $8.91 |
| Target Median | $7.63 |
| Target High | $18.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.78) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.24 | $-0.30 | $-0.20 | 26.4% | +4.1% | 3↑ 1↓ | $0.0B | 0.0% | 9 |
| Next Q 2026-09-30 |
$-0.23 | $-0.32 | $-0.18 | 35.0% | +1.8% | 3↑ 1↓ | $0.0B | 0.0% | 9 |
| Current FY 2026-12-31 |
$-0.96 | $-1.29 | $-0.67 | 33.5% | -0.5% | 3↑ 2↓ | $0.0B | 0.0% | 9 |
| Next FY 2027-12-31 |
$-0.89 | $-1.25 | $-0.39 | 7.6% | +3.6% | 4↑ 1↓ | $0.0B | 0.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.243 | |
| 7d ago | $-0.243 | |
| 30d ago | $-0.253 | +0.010 |
| 60d ago | $-0.250 | +0.007 |
| 90d ago | $-0.272 | +0.029 |
4 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 31, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Mar 31, 2026 | Needham | REITERATE | Buy | Buy |
| Feb 17, 2026 | William Blair | UPGRADE | Market Perform | Outperform |
| Jan 12, 2026 | Leerink Partners | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| May 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| Apr 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| Mar 1, 2026 | 5 | 7 | 2 | 1 | 0 | 80% | |
| Feb 1, 2026 | 4 | 7 | 3 | 1 | 0 | 73% | |
| Jan 1, 2026 | 3 | 7 | 3 | 1 | 0 | 71% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
43°
Neutral
Bearish
Neutral
Bullish
3 mentions
1 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 27, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 10, 2026 | 2 | 33° Cool | 0 | 2 | 2 |
Recent Reddit Threads
Biotech companies $IOVA and $NMRA DD
▲ 1
💬 1
⚡ 0.0
NMRA - Nearly Zero-Cost Bull Risk Reversal
▲ 1
💬 1
⚡ 0.0
NMRA - Bull Risk Reversal
▲ 7
💬 5
⚡ 0.0
May 20, 2026
short_volume
Short Volume: NMRA — 58.2% short (0.3M / 0.6M)
Short: 340,086 | Exempt: 8 | TRF Vol: 584,076 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings_calendar
NMRA Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
short_volume
Short Volume: NMRA — 55.3% short (0.4M / 0.8M)
Short: 435,514 | Exempt: 399 | TRF Vol: 788,066 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second qu
Apr 6, 2026
other
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
<p align="left">WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- <strong>Neumora Therapeutics, Inc. </strong>(Nasdaq: NMRA), a clinical-stage bi
Apr 1, 2026
Clinical Trial
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
Phase Phase 2 — COMPLETED
Mar 30, 2026
earnings
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivo
Mar 30, 2026
earnings_calendar
NMRA Q4 2025 Earnings Before Market Open — 2026-03-30
Mar 26, 2026
short_volume
Short Volume: NMRA — 67.1% short (0.4M / 0.6M)
Short: 382,558 | Exempt: 0 | TRF Vol: 570,106 | Short Ratio: 67.1% | Off-exchange volume (dark pool + OTC)
Mar 16, 2026
earnings
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
<p align="left">WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- <strong>Neumora Therapeutics, Inc. </strong>(Nasdaq: NMRA), a clinical-stage bi
Mar 11, 2026
earnings_calendar
NMRA Q4 2025 Earnings Before Market Open — 2026-03-11